Previous 10 | Next 10 |
TEL AVIV, Israel, Sept. 15, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT ) will present today a corporate overview, including an update on the OVAL pivotal study, at the H. C. Wainwright 22nd Annual Global Investment Conference being held virtually on September 14-16, 2020. ...
Mallinckrodt (NYSE: MNK ) -14% on FDA rejection of terlipressin for type of kidney failure. More news on: Mallinckrodt plc, Taoping Inc., Nikola Corporation, Stocks on the move, , Read more ...
VBL Therapeutics (NASDAQ: VBLT ) jumps 14% premarket on heels of new data demonstrating ex-vivo activity of its investigational anti-MOSPD2 (motile sperm domain-containing protein 2) mAbs in patients with relapsing-remitting and progressive multiple sclerosis (MS). Th...
Vascular Biogenics (NASDAQ: VBLT ) +32% on strong preclinical results of MOSPD2 program. More news on: Vascular Biogenics Ltd., Genetic Technologies Limited, Eastman Kodak Company, Stocks on the move, , Read more ...
TEL AVIV, Israel, Sept. 11, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT ), today presents for the first time new data demonstrating ex-vivo activity of its proprietary investigational anti-MOSPD2 mAbs in patients with relapsing-remitting and progressive multiple sclerosis...
The first two participants have been enrolled in a Phase 2 clinical trial evaluating the combination of VBL Therapeutics' ( VBLT +0.9% ) VB-111 and Bristol Myers Squibb's ( BMY -0.1% ) Opdivo (nivolumab) in metastatic colorectal cancer patients. More news on: Vascular Biogenics Ltd...
Study to investigate for the first time a combination of VB-111 with the checkpoint inhibitor, nivolumab. TEL AVIV, Israel, Sept. 10, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) announced today that the first two patients have been enrolled in the Phase 2 clinical trial...
Alignment with FDA on the path forward for the development of VB-601 TEL AVIV, Israel, Sept. 08, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) announced today the successful completion of a Type B pre-IND meeting with the U.S. Food and Drug Administration (FDA) regarding...
VBL Therapeutics reports progress for ovarian cancer drug candidate VBL Therapeutics ( VBLT ) announced the progress for its Phase 3 OVAL trial for platinum resistant ovarian cancer. The overall survival data from the trial was unblinded and reviewed by the independent Data Safety Monito...
Vascular Biogenics Ltd (VBLT) Q2 2020 Earnings Conference Call August 13, 2020, 08:30 ET Company Participants Michael Wood - LifeSci Advisors Dror Harats - CEO & Director Amos Ron - CFO & Company Secretary Conference Call Participants Kevin DeGeeter - Oppenheimer ...
News, Short Squeeze, Breakout and More Instantly...
Vascular Biogenics Ltd. Company Name:
VBLT Stock Symbol:
NASDAQ Market:
Approved Merger with Notable Labs and All Other Proposals Merger Expected to Close and Begin Trading as Combined Company Under the NTBL Ticker on Nasdaq Next Week, Subject to Effectiveness of Approved Israeli Corporate Actions MODI’IN, Israel and NEW YORK, Oct. 12, 2023 (GL...
MODI’IN, Israel and NEW YORK, Oct. 04, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (“VBL”), reminds its shareholders to vote in favor of the previously announced proposed merger (the “Merger”) with Notable Labs (“Notable”) at the annua...
Merger with Notable expected to close in mid-October, subject to shareholder approval Special shareholder meeting scheduled for October 12, 2023 MODI’IN, Israel and NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (“VBL”), today ann...